Glucose Lowering Strategies for Cardiac Benefits: Pathophysiological Mechanisms.

Published in: Physiology (Bethesda, Md.) (2019)

Recent trials in Type 2 diabetes (T2D) have shown cardiovascular benefits with specific GLP-1 receptor agonists and SGLT2 inhibitors. We discuss the landscape of outcome trials in T2D from a pathophysiology viewpoint, review current knowledge gaps in underlying mechanisms, propose a caloric fuel routing hypothesis, and highlight areas of future research.

Keyphrases

type diabetes
healthcare
left ventricular
cardiovascular disease
current status
glycemic control
blood glucose
single cell
insulin resistance
heart failure
adipose tissue
skeletal muscle